RecruitingNCT07375069

Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy

Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy - CardioMET Registry


Sponsor

Federico II University

Enrollment

3,000 participants

Start Date

Oct 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

CardioMET is an observational, multicenter, real-life registry, intending to collect data on patients with Type 2 Diabetes Mellitus, attending internal medicine and cardiology outpatient clinics. The aim of the registry is to characterize the cardiovascular risk profile and pharmacological management of Type 2 Diabetes Mellitus in Italy, in accordance with current ESC and AHA guidelines for primary and secondary prevention of CV disease.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age ≥ 18 years;
  • Diagnosis of type 2 diabetes mellitus (T2DM);
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria11

  • Known or suspected liver disease;
  • Patients with type 1 diabetes mellitus;
  • Cardiac surgery or percutaneous coronary revascularization scheduled within the next 3 months;
  • Patients with acute inflammatory or infectious diseases during the previous 3 months;
  • Patients with chronic inflammatory, immune, or infectious diseases;
  • Patients with ongoing malignant neoplasms;
  • History of alcohol, drug, or medication abuse;
  • Clinically significant hematological disorders;
  • Systemic steroid treatment within the last 6 months;
  • Acute-phase metabolic disorders;
  • Any condition that may put the patient at risk by participating in the study.

Interventions

OTHERdata collection

Data collection on diabetes therapy and follow-up


Locations(1)

Federico II University of Naples, Department of Advanced Biomedical Sciences

Napoli, Napoli, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07375069


Related Trials